ACAD
Price
$25.90
Change
+$1.12 (+4.52%)
Updated
Feb 26, 6:59 PM EST
Earnings call today
ARCT
Price
$40.94
Change
+$3.52 (+9.41%)
Updated
Feb 26, 6:59 PM EST
9 days until earnings call
Ad is loading...

Analysis and predictions ACAD vs ARCT

Header iconACAD vs ARCT Comparison
Open Charts ACAD vs ARCTBanner chart's image
ACADIA Pharmaceuticals
Price$25.90
Change+$1.12 (+4.52%)
Volume$934.71K
CapitalizationN/A
Arcturus Therapeutics Holdings
Price$40.94
Change+$3.52 (+9.41%)
Volume$303.34K
CapitalizationN/A
View a ticker or compare two or three
ACAD vs ARCT Comparison Chart

Loading...

ACADDaily Signal changed days agoGain/Loss if shorted
 
Show more...
ARCTDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ACAD vs. ARCT commentary
Feb 27, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and ARCT is a StrongSell.

COMPARISON
Comparison
Feb 27, 2024
Stock price -- (ACAD: $25.90 vs. ARCT: $40.94)
Brand notoriety: ACAD and ARCT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 101% vs. ARCT: 170%
Market capitalization -- ACAD: $4.07B vs. ARCT: $999.99M
ACAD [@Biotechnology] is valued at $4.07B. ARCT’s [@Biotechnology] market capitalization is $999.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $550.21B to $0. The average market capitalization across the [@Biotechnology] industry is $2.58B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 0 FA rating(s) are green whileARCT’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 0 green, 5 red.
  • ARCT’s FA Score: 1 green, 4 red.
According to our system of comparison, ARCT is a better buy in the long-term than ACAD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 5 TA indicator(s) are bullish while ARCT’s TA Score has 4 bullish TA indicator(s).

  • ACAD’s TA Score: 5 bullish, 4 bearish.
  • ARCT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ACAD is a better buy in the short-term than ARCT.

Price Growth

ACAD (@Biotechnology) experienced а +3.15% price change this week, while ARCT (@Biotechnology) price change was +10.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.08%. For the same industry, the average monthly price growth was +16.73%, and the average quarterly price growth was +41.60%.

Reported Earning Dates

ACAD is expected to report earnings on May 01, 2024.

ARCT is expected to report earnings on May 06, 2024.

Industries' Descriptions

@Biotechnology (+4.08% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ACAD with price predictions.
OPEN
A.I.dvisor published
a Summary for ARCT with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ACAD($4.07B) has a higher market cap than ARCT($1B). ARCT YTD gains are higher at: 29.845 vs. ACAD (-17.279). ARCT has higher annual earnings (EBITDA): 106M vs. ACAD (-149.98M). ACAD has more cash in the bank: 346M vs. ARCT (312M). ARCT has less debt than ACAD: ARCT (51.2M) vs ACAD (57.1M). ACAD has higher revenues than ARCT: ACAD (632M) vs ARCT (293M).
ACADARCTACAD / ARCT
Capitalization4.07B1B407%
EBITDA-149.98M106M-141%
Gain YTD-17.27929.845-58%
P/E RatioN/A10.89-
Revenue632M293M216%
Total Cash346M312M111%
Total Debt57.1M51.2M112%
FUNDAMENTALS RATINGS
ACAD vs ARCT: Fundamental Ratings
ACAD
ARCT
OUTLOOK RATING
1..100
5873
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
8864
SMR RATING
1..100
9620
PRICE GROWTH RATING
1..100
4836
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (56) in the Pharmaceuticals Major industry is in the same range as ACAD (69) in the Biotechnology industry. This means that ARCT’s stock grew similarly to ACAD’s over the last 12 months.

ARCT's Profit vs Risk Rating (64) in the Pharmaceuticals Major industry is in the same range as ACAD (88) in the Biotechnology industry. This means that ARCT’s stock grew similarly to ACAD’s over the last 12 months.

ARCT's SMR Rating (20) in the Pharmaceuticals Major industry is significantly better than the same rating for ACAD (96) in the Biotechnology industry. This means that ARCT’s stock grew significantly faster than ACAD’s over the last 12 months.

ARCT's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as ACAD (48) in the Biotechnology industry. This means that ARCT’s stock grew similarly to ACAD’s over the last 12 months.

ARCT's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as ACAD (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADARCT
RSI
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
N/A
Bullish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 16 days ago
78%
Bullish Trend 16 days ago
86%
Declines
ODDS (%)
Bearish Trend 5 days ago
73%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Ad is loading...
ACADDaily Signal changed days agoGain/Loss if shorted
 
Show more...
ARCTDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ISGLX14.350.12
+0.84%
Columbia Integrated Small Cap Gr Adv
GTSVX35.170.23
+0.66%
Invesco Small Cap Growth R5
MUOAX25.23-0.03
-0.12%
Morgan Stanley Instl US Core A
TCRAX50.28-0.19
-0.38%
American Century Growth A
FRBAX23.34-0.22
-0.93%
JHancock Regional Bank A

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with VRTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then VRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+4.52%
VRTX - ACAD
43%
Loosely correlated
+0.78%
STTK - ACAD
41%
Loosely correlated
+3.78%
DNLI - ACAD
40%
Loosely correlated
-0.24%
CCCC - ACAD
40%
Loosely correlated
+5.78%
FOLD - ACAD
38%
Loosely correlated
+1.85%
More

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with AXON. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+9.41%
AXON - ARCT
49%
Loosely correlated
+0.35%
ORMP - ARCT
45%
Loosely correlated
+2.60%
VCYT - ARCT
45%
Loosely correlated
+6.22%
NTLA - ARCT
45%
Loosely correlated
+5.98%
BEAM - ARCT
42%
Loosely correlated
+5.33%
More